An oligomer combination for detecting a human papillomavirus target nucleic acid in a sample suspected of containing HPV type 31 or HPV type 33 and at least one of HPV type 52 and HPV type 58, said oligomer combination comprising: (i) first and second amplification oligomers for specifically amplifying an HPV33 nucleic acid target region, wherein (a) the first HPV33 amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:66 and that includes at least the sequence of SEQ ID NO:67 and SEQ ID NO:68; and (b) the second HPV33 amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:70 and that includes at least the sequence of SEQ ID NO:71 and SEQ ID NO:72; and (ii) first and second amplification oligomers for specifically amplifying an HPV31 nucleic acid target region, wherein (a) the first HPV31 amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:74 and that includes at least the sequence of SEQ ID NO:75 and SEQ ID NO:76; and (b) the second HPV31 amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 30 contiguous nucleotides contained in the sequence of SEQ ID NO:78 and that includes at least the sequence of SEQ ID NO:79 and SEQ ID NO:80. (i) first and second amplification oligomers for specifically amplifying an HPV33 nucleic acid target region, wherein (a) the first HPV33 amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:66 and that includes at least the sequence of SEQ ID NO:67 and SEQ ID NO:68; and (b) the second HPV33 amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:70 and that includes at least the sequence of SEQ ID NO:71 and SEQ ID NO:72; and (a) the first HPV33 amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:66 and that includes at least the sequence of SEQ ID NO:67 and SEQ ID NO:68; and (b) the second HPV33 amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:70 and that includes at least the sequence of SEQ ID NO:71 and SEQ ID NO:72; and (ii) first and second amplification oligomers for specifically amplifying an HPV31 nucleic acid target region, wherein (a) the first HPV31 amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:74 and that includes at least the sequence of SEQ ID NO:75 and SEQ ID NO:76; and (b) the second HPV31 amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 30 contiguous nucleotides contained in the sequence of SEQ ID NO:78 and that includes at least the sequence of SEQ ID NO:79 and SEQ ID NO:80. (a) the first HPV31 amplification oligomer comprises a first target-hybridizing sequence that is from about 15 to about 27 contiguous nucleotides contained in the sequence of SEQ ID NO:74 and that includes at least the sequence of SEQ ID NO:75 and SEQ ID NO:76; and (b) the second HPV31 amplification oligomer comprises a second target-hybridizing sequence that is from about 15 to about 30 contiguous nucleotides contained in the sequence of SEQ ID NO:78 and that includes at least the sequence of SEQ ID NO:79 and SEQ ID NO:80.